Lotus Eye Hospital and Institute Limited

NSEI:LOTUSEYE Rapporto sulle azioni

Cap. di mercato: ₹1.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lotus Eye Hospital and Institute Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Lotus Eye Hospital and Institute.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Healthcare crescita degli utili26.1%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

None

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Lotus Eye Hospital and Institute non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NSEI:LOTUSEYE - Stime future degli analisti e dati finanziari passati (INR Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
6/30/202448522N/AN/AN/A
3/31/202448229057N/A
12/31/202348535N/AN/AN/A
9/30/202348640-157N/A
6/30/202347741N/AN/AN/A
3/31/2023470411344N/A
12/31/202246440N/AN/AN/A
9/30/2022459421369N/A
6/30/202244946N/AN/AN/A
3/31/202238930-344N/A
12/31/202138936N/AN/AN/A
9/30/2021372323749N/A
6/30/202133520N/AN/AN/A
3/31/2021324162327N/A
12/31/2020300-5N/AN/AN/A
9/30/2020301-14826N/A
6/30/2020335-6N/AN/AN/A
3/31/2020406112650N/A
12/31/201942021N/AN/AN/A
9/30/201941520N/AN/AN/A
6/30/201940111N/AN/AN/A
3/31/20193847-542N/A
12/31/20183827N/AN/AN/A
9/30/20183819N/AN/AN/A
6/30/201838414N/AN/AN/A
3/31/201838017N/A58N/A
12/31/20173738N/AN/AN/A
9/30/20173594N/AN/AN/A
6/30/20173506N/AN/AN/A
3/31/20173404N/A30N/A
12/31/20163307N/AN/AN/A
9/30/20163247N/AN/AN/A
6/30/20163140N/AN/AN/A
3/31/20163111N/A34N/A
12/31/2015311-5N/AN/AN/A
9/30/2015315-6N/AN/AN/A
6/30/2015308-14N/AN/AN/A
3/31/2015302-20N/A24N/A
12/31/2014298-12N/AN/AN/A
9/30/2014290-9N/AN/AN/A
6/30/20142891N/AN/AN/A
3/31/20142880N/A44N/A
12/31/20132874N/AN/AN/A
9/30/20132852N/AN/AN/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista LOTUSEYE è superiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di LOTUSEYE cresceranno più velocemente del mercato Indian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di LOTUSEYE cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di LOTUSEYE cresceranno più rapidamente del mercato Indian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di LOTUSEYE cresceranno più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di LOTUSEYE è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita